Europe Pneumococcal Vaccine Market Size, Share, Trends, Industry Analysis Report: By Type, Product, End User, and Country

Description

List of Tables

The Europe pneumococcal vaccine market size is expected to reach USD 2.9 billion by 2032, according to a new study by Polaris Market Research. The report "Europe Pneumococcal Vaccine Market Size, Share, Trends, Industry Analysis Report: By Type (Pneumococcal Conjugate Vaccines and Pneumococcal Polysaccharide Vaccines), Product, End User, and Country - Market Forecast, 2023-2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Pneumococcal vaccination programs play a crucial role in preventing diseases caused by streptococcus pneumoniae, which lead to serious health issues such as pneumonia, meningitis, and sepsis. Most European countries include PCVs in their national immunization programs (NIPs), targeting primarily children under five and older adults.

The introduction of higher-valent pneumococcal conjugate vaccines (PCVs) is estimated to drive the Europe pneumococcal vaccine market in the coming years. Higher-valent PCVs protect against a greater number of pneumococcal serotypes, reducing the risk of disease from strains that were previously not covered. This increased coverage is appealing to healthcare providers and patients alike, thereby boosting demand.

The growing geriatric population in Europe is projected to propel the Europe pneumococcal vaccine market during the forecast period. Pneumococcal diseases have higher morbidity and mortality rates among the elderly. Vaccination is essential for reducing these health risks, leading to increased demand. Thus, as the senior population increases in Europe, the demand for pneumococcal vaccines increases. For instance, the population of older people aged 65 years and above in the EU is estimated to increase significantly, rising from 90.5 million at the start of 2019 to reach 129.8 million by 2050.

The collaborations between public health authorities and private vaccine manufacturers are projected to fuel market growth as this collaboration enhances distribution and accessibility, supporting market growth.

The growing prevalence of pneumonia in Europe propels the demand for pneumococcal vaccines. Higher pneumonia prevalence often leads health authorities to strengthen recommendations for pneumococcal vaccination, especially for vulnerable populations, which increases uptake. According to the National Library of Medicine, pneumonia is responsible for ~230,000 deaths in Europe each year.

Increased public awareness and education about the importance of vaccinations and the risks of pneumococcal diseases contribute to higher vaccination rates, which ultimately boost demand for pneumococcal vaccines.

Europe Pneumococcal Vaccine Market Report Highlights

Based on type, the pneumococcal conjugate vaccines segment dominated the Europe pneumococcal vaccine market in 2023 due to their effectiveness in preventing a broader range of pneumococcal diseases and advances in vaccine technology.

In terms of end users, the public sector segment accounted for a larger market share in 2023, owing to the rising funding from international health organizations.

The UK dominated the market in Europe in 2023, owing to a well-established immunization program, a growing elderly population, and ongoing research and advancements in vaccine technology.

The market in Germany is projected to register the fastest growth during the forecast period, attributable to the robust healthcare system and the growing awareness of the importance of vaccinations, particularly among healthcare professionals and the general public.

Astellas Pharma Inc., CSL Ltd, GSK Plc, Merck & Co. Inc., Panacea Biotech Ltd, GPN Vaccines, SK Bioscience, Pfizer Inc., Sanofi S.A., Serum Institute of India Pvt. Ltd, Talley Group Ltd, and Walvax Biotechnology Co. Ltd. are among the global market players.

Polaris Market Research has segmented the Europe pneumococcal vaccine market report on the basis of type, product, end user, and country:

By Type Outlook (Revenue - USD Billion, 2019-2032)

Pneumococcal Conjugate Vaccines
Pneumococcal Polysaccharide Vaccines

By Product Outlook (Revenue - USD Billion, 2019-2032)

Prevnar 13
Synflorix
Pneumovax 23
VAXNEUVANCE
PNEUMOSIL
Other

By End User Outlook (Revenue - USD Billion, 2019-2032)

Public Sector
Private Sector

By Country Outlook (Revenue - USD Billion, 2019-2032)

France
Germany
UK
Italy
Netherlands
Spain
Russia

Product Code: PM5078

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Europe Pneumococcal Vaccine Market Insights

4.1. Europe Pneumococcal Vaccine Market - Market Snapshot
4.2. Europe Pneumococcal Vaccine Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. The growing prevalence of pneumonia is driving the market.
  - 4.2.1.2. The growing R&D for developing novel vaccines propels the market.
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. The high cost of investment in vaccine development is hindering the Europe Pneumococcal Vaccine market growth.
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Europe Pneumococcal Vaccine Market Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Europe Pneumococcal Vaccine Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. Europe Pneumococcal Vaccine Market, by Type, 2019-2032 (USD billion)
5.3. Pneumococcal Conjugate Vaccine
- 5.3.1. Europe Pneumococcal Vaccine Market, by Pneumococcal Conjugate Vaccine, by Region, 2019-2032 (USD billion)
5.4. Pneumococcal Polysaccharide Vaccine
- 5.4.1. Europe Pneumococcal Vaccine Market, by Pneumococcal Polysaccharide Vaccine, by Region, 2019-2032 (USD billion)

6. Europe Pneumococcal Vaccine Market, by Product

6.1. Key Findings
6.2. Introduction
- 6.2.1. Europe Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
6.3. Prevnar 13
- 6.3.1. Europe Pneumococcal Vaccine Market, by Prevnar 13, by Region, 2019-2032 (USD billion)
6.4. Synflorix
- 6.4.1. Europe Pneumococcal Vaccine Market, by Synflorix, by Region, 2019-2032 (USD billion)
6.5. Pneumovax 23
- 6.5.1. Europe Pneumococcal Vaccine Market, by Pneumovax 23, by Region, 2019-2032 (USD billion)
6.6. VAXNEUVANCE
- 6.6.1. Europe Pneumococcal Vaccine Market, by VAXNEUVANCE, by Region, 2019-2032 (USD billion)
6.7. PNEUMOSIL
- 6.7.1. Europe Pneumococcal Vaccine Market, by PNEUMOSIL, by Region, 2019-2032 (USD billion)
6.8. Other
- 6.8.1. Europe Pneumococcal Vaccine Market, by Other, by Region, 2019-2032 (USD billion)

7. Europe Pneumococcal Vaccine Market, by End-user

7.1. Key Findings
7.2. Introduction
- 7.2.1. Europe Pneumococcal Vaccine Market, by End-user, 2019-2032 (USD billion)
7.3. Public Sector
- 7.3.1. Europe Pneumococcal Vaccine Market, by Public Sector, by Region, 2019-2032 (USD billion)
7.4. Private Sector
- 7.4.1. Europe Pneumococcal Vaccine Market, by Private Sector, by Region, 2019-2032 (USD billion)

8. Europe Pneumococcal Vaccine Market, by Geography

8.1. Key Findings
8.2. Introduction
- 8.2.1. Europe Pneumococcal Vaccine Market Assessment, By Geography, 2019-2032 (USD billion)
8.3. Europe Pneumococcal Vaccine Market - Europe
- 8.3.1. Europe Pneumococcal Vaccine Market, by Type, 2019-2032 (USD billion)
- 8.3.2. Europe Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
- 8.3.3. Europe Pneumococcal Vaccine Market, by End-user, 2019-2032 (USD billion)
- 8.3.4. Europe Pneumococcal Vaccine Market - UK
  - 8.3.4.1. UK: Pneumococcal Vaccine Market, by Type, 2019-2032 (USD billion)
  - 8.3.4.2. UK: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.3.4.3. UK: Pneumococcal Vaccine Market, by End-user, 2019-2032 (USD billion)
- 8.3.5. Europe Pneumococcal Vaccine Market - France
  - 8.3.5.1. France: Pneumococcal Vaccine Market, by Type, 2019-2032 (USD billion)
  - 8.3.5.2. France: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.3.5.3. France: Pneumococcal Vaccine Market, by End-user, 2019-2032 (USD billion)
- 8.3.6. Europe Pneumococcal Vaccine Market - Germany
  - 8.3.6.1. Germany: Pneumococcal Vaccine Market, by Type, 2019-2032 (USD billion)
  - 8.3.6.2. Germany: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.3.6.3. Germany: Pneumococcal Vaccine Market, by End-user, 2019-2032 (USD billion)
- 8.3.7. Europe Pneumococcal Vaccine Market - Italy
  - 8.3.7.1. Italy: Pneumococcal Vaccine Market, by Type, 2019-2032 (USD billion)
  - 8.3.7.2. Italy: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.3.7.3. Italy: Pneumococcal Vaccine Market, by End-user, 2019-2032 (USD billion)
- 8.3.8. Europe Pneumococcal Vaccine Market - Spain
  - 8.3.8.1. Spain: Pneumococcal Vaccine Market, by Type, 2019-2032 (USD billion)
  - 8.3.8.2. Spain: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.3.8.3. Spain: Pneumococcal Vaccine Market, by End-user, 2019-2032 (USD billion)
- 8.3.9. Europe Pneumococcal Vaccine Market - Netherlands
  - 8.3.9.1. Netherlands: Pneumococcal Vaccine Market, by Type, 2019-2032 (USD billion)
  - 8.3.9.2. Netherlands: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.3.9.3. Netherlands: Pneumococcal Vaccine Market, by End-user, 2019-2032 (USD billion)
- 8.3.10. Europe Pneumococcal Vaccine Market - Russia
  - 8.3.10.1. Russia: Pneumococcal Vaccine Market, by Type, 2019-2032 (USD billion)
  - 8.3.10.2. Russia: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.3.10.3. Russia: Pneumococcal Vaccine Market, by End-user, 2019-2032 (USD billion)
- 8.3.11. Europe Pneumococcal Vaccine Market - Rest of Europe
  - 8.3.11.1. Rest of Europe: Pneumococcal Vaccine Market, by Type, 2019-2032 (USD billion)
  - 8.3.11.2. Rest of Europe: Pneumococcal Vaccine Market, by Product, 2019-2032 (USD billion)
  - 8.3.11.3. Rest of Europe: Pneumococcal Vaccine Market, by End-user, 2019-2032 (USD billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. Astellas Pharma Inc.
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Type Benchmarking
- 10.1.4. Recent Development
10.2. CSL Ltd
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Type Benchmarking
- 10.2.4. Recent Development
10.3. GSK Plc
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Type Benchmarking
- 10.3.4. Recent Development
10.4. Merck & Co. Inc.
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Type Benchmarking
- 10.4.4. Recent Development
10.5. Panacea Biotech Ltd
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Type Benchmarking
- 10.5.4. Recent Development
10.6. GPN Vaccines
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Type Benchmarking
- 10.6.4. Recent Development
10.7. SK Bioscience
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Type Benchmarking
- 10.7.4. Recent Development
10.8. Bio Pfizer Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Type Benchmarking
- 10.8.4. Recent Development
10.9. Sanofi S.A
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Type Benchmarking
- 10.9.4. Recent Development
10.10. Serum Life Sciences Ltd
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Type Benchmarking
- 10.10.4. Recent Development
10.11. Talley Group Ltd.
- 10.11.1. Company Overview
- 10.11.2. Financial Performance
- 10.11.3. Type Benchmarking
- 10.11.4. Recent Development
10.12. Walvax Biotechnology Co. Ltd.
- 10.12.1. Company Overview
- 10.12.2. Financial Performance
- 10.12.3. Type Benchmarking
- 10.12.4. Recent Development